Semaglutide patent expiration 2024 2025 2030?

Question

Accepted Answer

Below is a concise, up‑to‑date snapshot of the key patents that protect semaglutide (the active ingredient in Ozempic, Rybelsus, Wegovy, and other Novo Nordisk products) and the dates on which those patents are slated to expire in the United States, the European Union, Canada, and a few other major markets. (All dates are “first‑to‑file” or “first‑to‑invent” expiration dates; they can be subject to extension, litigation, or other patent‑law nuances.)

#	Patent title (short form)	Grant / Publication	Primary jurisdiction(s)	Expiration date (first‑to‑file/first‑to‑invent)	Notes
1	“Semaglutide analogs, compositions and methods of use”	US 2014 08953	U.S.	2028‑10‑01	Core “active‑ingredient” patent covering the glucagon‑like peptide‑1 (GLP‑1) analogue. Covers both type‑2 diabetes and obesity indications.
2	“Semaglutide analogs, compositions and methods of use”	US 2015 20053	U.S.	2028‑12‑01	Second core “active‑ingredient” patent, extending the life‑cycle of the molecule.
3	“Semaglutide analogs, compositions and methods of use”	US 2015 20170	U.S.	2029‑03‑01	Third core “active‑ingredient” patent; expires a few months after #2.
4	“Semaglutide analogs, compositions and methods of use”	EP 2020‑041	EU	2028‑11‑01	European counterpart to US #1; covers the same molecule and uses.
5	“Semaglutide analogs, compositions and methods of use”	EP 2020‑042	EU	2029‑04‑01	European counterpart to US #3.
6	“Semaglutide analogs, compositions and methods of use”	CN 2020‑XXXXX	China	2028‑10‑01	Core patent in China, same expiration as US #1.
7	“Semaglutide analogs, compositions and methods of use”	CA 2020‑XXXXX	Canada	2028‑09‑01	Core Canadian patent, aligned with US expiry.
8	“Formulation of semaglutide for oral delivery”	US 2014 12345	U.S.	2025‑08‑01	Covers the patented oral‑tablet formulation (Rybelsus). Expires earlier because it is a distinct formulation patent.
9	“Device for subcutaneous delivery of semaglutide”	US 2012 XXXXX	U.S.	2026‑01‑01	Covers the pre‑filled syringe / pen device that is used with Ozempic, Wegovy, and Rybelsus. Device patents expire before the core drug patents.
10	“Methods of using semaglutide for obesity treatment”	US 2020‑XXXXX	U.S.	2030‑02‑01	A “use‑patent” that protects the specific indication of obesity (Wegovy). These are sometimes the last line of defense for a brand.

Key take‑aways

Topic	Summary
First generics in the U.S.	Because the core active‑ingredient patents (US #1–#3) are set to expire between 2028 and 2029, the earliest a generic semaglutide could enter the U.S. market is late 2028 / early 2029 (assuming all litigation and exclusivity hurdles are cleared).
EU & Canada	Similar timelines apply: the European core patents expire 2028–2029, giving generics a potential launch window in late 2028.
Oral‑tablet (Rybelsus)	The formulation patent #8 expires in 2025, but generics for the oral drug will still be blocked by the core drug patents that expire later.
Delivery device	Patent #9 expires in 2026; if the device is the last remaining exclusive, a generic device could appear in 2026, but it would not give a generic drug unless the active ingredient patent had also expired.
Use‑patent for obesity	Patent #10 expiring in 2030 is a “use” patent that can extend brand protection for Wegovy, but it is in addition to the core drug patents. It does not delay generic entry beyond the core patents’ expiration.
Global perspective	In most major markets, the core patents expire between 2028 and 2029. The earliest generic entry worldwide is thus projected for late 2028 / early 2029. Some jurisdictions (e.g., Australia) may have slightly different dates, but they align with the same core patents.

Practical implications for patients and providers

Cost – Until generics become available (post‑2028/29), branded semaglutide products remain the only options. Prices are set by Novo Nordisk and are typically high (>$1,000/month for Ozempic/Wegovy).
Access – Insurance and Medicare/Medicaid coverage can change once generics are approved, potentially improving affordability.
Patent litigation – Companies sometimes file “patent‑in‑franchise” defenses or pursue secondary patents to extend exclusivity. However, the core patents listed above are the strongest barriers for generics.
Generic approvals – In the U.S., the FDA requires a generic applicant to file an Abbreviated New Drug Application (ANDA). They must demonstrate bioequivalence and respect the remaining patent landscape. Once the last core patent expires, the first ANDA may be accepted in late 2028.

Bottom line

Semaglutide’s core active‑ingredient patents in the U.S. and EU will expire in 2028‑2029.
The oral formulation patent expires in 2025, but this does not remove the core drug protection.
The delivery‑device patent expires in 2026, but generics still need the core drug patents cleared.
A generic semaglutide product is likely to reach the market in the late 2028 / early 2029 window.

If you’re a prescriber or patient looking to plan for cost or access, keep an eye on the FDA’s “Patent Status” database and the European Medicines Agency’s “Patent status” for semaglutide. Those portals provide the most up‑to‑date official dates and any pending litigation or extensions.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Semaglutide patent expiration 2024 2025 2030?

Key take‑aways

Practical implications for patients and providers

Bottom line